ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
31.47
-0.02 (-0.06%)
Nov 5, 2024, 1:18 PM EST - Market open

ArriVent BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Net Income
-74.89-69.33-36.91-68.81
Asset Writedown & Restructuring Costs
---57.21
Stock-Based Compensation
1.930.90.420.07
Change in Accounts Payable
-2.661.382.80.39
Change in Other Net Operating Assets
7.5411.22-9.95-5.65
Operating Cash Flow
-68.07-55.84-43.63-16.78
Sale (Purchase) of Intangibles
----53.33
Investing Cash Flow
25---53.33
Total Debt Issued
---0.27
Total Debt Repaid
----0.27
Issuance of Common Stock
186.320.350.020
Other Financing Activities
-2.41-2.41--
Financing Cash Flow
183.9142.86169.72119.82
Net Cash Flow
140.84-12.98126.0949.71
Free Cash Flow
-68.07-55.84-43.63-16.78
Free Cash Flow Per Share
-4.27-26.08-34.16-23.60
Levered Free Cash Flow
-46.73-32.8-29.81-
Unlevered Free Cash Flow
-46.73-32.8-29.81-
Change in Net Working Capital
-5.22-12.927.16-
Source: S&P Capital IQ. Standard template. Financial Sources.